PreveCeutical Medical’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Breakthrough Sol-gel Drug Delivery Platform Featured in Proactive Investors Interview
PreveCeutical was recently featured in an interview by Proactive Investors The company is currently developing its Sol-gel drug delivery platform for delivery of cannabinoids Sol-gel technology is paving the way for direct nose-to-brain drug delivery Innovative health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was recently featured by Proactive Investors in a “Corporate News Update” regarding the company’s potentially game-changing Sol-gel drug delivery platform (http://ibn.fm/ryrqu). The company earlier provided a written press release updating the Sol-gel program (http://ibn.fm/Bww8y). Sol-gel, a nickname for soluble gel, is taken through nasal (systemic) administration and quickly gels once it comes in…